Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.909,74 -550,34 (-1,43%) EUR/USD
1,0705 +0,0005 (+0,04%) Bitcoin EUR
60.411,73 -1.833,93 (-2,95%) CMC Crypto 200
1.391,55 -32,55 (-2,29%)
Viridian Therapeutics, Inc. (0K1R.L)
| Chiusura precedente | 14,62 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 682 |
| Capitalizzazione | 2,975M |
| Beta (5 anni mensile) | 1,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,14 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireViridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds multiple senior executives to its leadership team, including its first Chief Commercial Officer, as part of its ongoing growth - - Conference call today at 4:30pm ET - WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a bi
- GlobeNewswire
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- Partnership to support one of the Company’s preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25m
- GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,000 shares of the Company’s co
